– Filing triggers $20 million milestone payment to Exelixis –
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 26, 2018--
Exelixis,
Inc. (NASDAQ: EXEL) today announced that its partner Daiichi Sankyo
Company, Limited (“Daiichi Sankyo”) has submitted its regulatory
application for esaxerenone (INN; code name CS-3150) as a treatment for
patients with hypertension to the Japanese Pharmaceutical and Medical
Devices Agency. Esaxerenone is a compound identified during the prior
research collaboration between Exelixis and Daiichi Sankyo, and has been
subsequently developed by Daiichi Sankyo. As a result of the submission,
Exelixis will receive a $20 million milestone payment per the two
companies’ collaboration agreement.
Daiichi Sankyo’s application is based on the results of phase 3 studies
including ESAX-HTN, a randomized, double-blind, three-arm parallel group
comparison study evaluating the efficacy and safety of esaxerenone
versus eplerenone in patients with essential hypertension in Japan.
Top-line results for ESAX-HTN were announced in September 2017, and
Daiichi Sankyo plans to disclose detailed study results at a future
scientific meeting.
“Daiichi Sankyo has been an excellent partner throughout the years, and
continues to be effective in its clinical and regulatory progress.
Daiichi Sankyo’s regulatory filing for esaxerenone is an important step
toward a potential new therapeutic option for patients with hypertension
in Japan, where more than 43 million people are estimated to have high
blood pressure,” said Michael M. Morrissey, Ph.D., President and Chief
Executive Officer of Exelixis. “This milestone is another example of the
critical role our partnered compounds can play by generating additional
revenues for us to reinvest in our business as we work to bring new
medicines to market for difficult-to-treat cancers.”
In March 2006, Daiichi Sankyo and Exelixis entered into a research
collaboration agreement to discover, develop and commercialize novel
therapies targeting the mineralocorticoid receptor (MR). Under the terms
of the agreement, Daiichi Sankyo has exclusive global development,
manufacturing and commercialization rights for the compounds.
Esaxerenone, a non-steroidal, selective novel MR blocker, is one of the
compounds identified during the research collaboration, and has
subsequently been developed by Daiichi Sankyo. As esaxerenone advances,
Exelixis is eligible for substantial commercialization milestones, as
well as double-digit royalties on sales.
About Hypertension in Japan
According to the 2012 Japan National Health and Nutrition Survey, there
are an estimated 43 million patients with hypertension in the country,
which accounts for 60% of men and 45% of women over the age of 30 in the
general Japanese population.1 Only approximately 30% of men
and 40% of women with hypertension who are treated with antihypertensive
medication typically achieve the goal of systolic and diastolic blood
pressure lower than 140/90mm Hg.
Hypertension is one of the major risk factors for cardiovascular
disease, such as stroke and coronary heart disease, and the condition
also raises the risk of chronic kidney disease and end-stage renal
disease.1 Essential hypertension is the most common
form of hypertension, affecting 90% of hypertensive patients, and is
associated with heterogeneous contributory factors such as genetics and
lifestyle habits, while secondary hypertension is associated with
identified underlying disease factors.1
About Esaxerenone (CS-3150)
Esaxerenone is an oral, non-steroidal, selective blocker of the
mineralocorticoid receptor (MR), a nuclear hormone receptor implicated
in a variety of cardiovascular and metabolic diseases. MR blockers can
be used to treat hypertension and congestive heart failure due to their
vascular protective effects. Recent studies have also suggested
beneficial effects of adding MR blockers to the treatment regimen for
Type 2 diabetic patients with nephropathy. As a non-steroidal, selective
MR blocker, esaxerenone may have potential for the treatment of
hypertension, diabetic nephropathy and congestive heart failure, and may
provide protection from end organ damage due to vascular complications.
Esaxerenone is one of the compounds identified during Exelixis’ research
collaboration with Daiichi Sankyo, which the companies entered into in
March 2006. Under the terms of the agreement, Exelixis granted Daiichi
Sankyo an exclusive, worldwide license to certain intellectual property
primarily relating to compounds that modulate MR. In exchange, Exelixis
received a $20 million upfront payment, research funding for a joint
research period, and the potential for substantial clinical development,
regulatory and commercialization milestone payments, as well as
double-digit royalties on sales. Since the conclusion of the joint
research period in November 2007, Daiichi Sankyo has been responsible
for all subsequent preclinical and clinical development, and will also
oversee regulatory, manufacturing and commercialization activities for
the compound.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Forward-Looking Statements
This press release contains forward-looking statements, including,
without limitation, statements related to: Daiichi Sankyo’s payment of a
$20 million milestone to Exelixis in connection with its submission of a
regulatory application in Japan for esaxerenone; Daiichi Sankyo’s
intention to present ESAX-HTN results at a future scientific meeting;
esaxerenone’s potential as a new therapeutic option for patients with
hypertension, diabetic nephropathy and congestive heart failure, and its
ability to provide protection from end organ damage due to vascular
complications; the potential for esaxerenone to meaningfully contribute
to Exelixis’ business and directly support the development of
future Exelixis medicines; Exelixis’ eligibility for future
commercialization milestones, plus royalties on sales under its
collaboration with Daiichi Sankyo; Exelixis’ mission of helping cancer
patients recover stronger and live longer; growing revenues from
Exelixis’ products and plans to reinvest in its business to maximize the
potential of the company’s pipeline, including through targeted business
development activities and internal drug discovery; and Exelixis’
mission to deliver the next generation of Exelixis medicines and help
patients recover stronger and live longer. Words such as “will”, plans,”
“can”, eligible,” “future,” “intention,” “potential,” “mission,” “may,”
or other similar expressions identify forward-looking statements, but
the absence of these words does not necessarily mean that a statement is
not forward-looking. In addition, any statements that refer to
expectations, projections or other characterizations of future events or
circumstances are forward-looking statements. These forward-looking
statements are based upon Exelixis’ current plans, assumptions, beliefs,
expectations, estimates and projections. Forward-looking statements
involve risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in the forward-looking
statements as a result of these risks and uncertainties, which include,
without limitation: risks and uncertainties related to regulatory review
and approval processes; Exelixis’ dependence on its relationship
with Daiichi Sankyo with respect to esaxerenone, including the level
of Daiichi Sankyo’s investment in the resources necessary to
successfully commercialize esaxerenone in territories where it is
ultimately approved; market acceptance of CABOMETYX® (cabozantinib),
COMETRIQ® (cabozantinib), and COTELLIC® (cobimetinib) and the
availability of coverage and reimbursement for these products; the
availability of data at the referenced times; the risk that
unanticipated developments could adversely affect the commercialization
of CABOMETYX, COMETRIQ, and COTELLIC; the level of costs associated with
Exelixis’ commercialization, research and development and other
activities; Exelixis’ ability to protect the company’s intellectual
property rights; market competition; changes in economic and business
conditions, and other factors discussed under the caption “Risk Factors”
in Exelixis’ annual report on Form 10-K filed with the Securities and
Exchange Commission (SEC) on February 26, 2018, and in Exelixis’ future
filings with the SEC. The forward-looking statements made in this press
release speak only as of the date of this press release. Exelixis
expressly disclaims any duty, obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Exelixis’ expectations with
regard thereto or any change in events, conditions or circumstances on
which any such statements are based.
Exelixis and the Exelixis logo are registered U.S. trademarks.
References:
1 The Japanese Society of Hypertension Guidelines for the
Management of Hypertension (JSH 2014). Hypertens Research 2014; 37:
253-392.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180226006626/en/
Source: Exelixis, Inc.
Investors Contact:
Exelixis, Inc.
Susan
Hubbard, 650-837-8194
EVP, Public Affairs and Investor
Relations
shubbard@exelixis.com
or
Media
Contact:
For Exelixis, Inc.
Hal Mackins,
415-994-0040
hal@torchcommunications.com